Ankylosing Spondylitis - Pipeline Insight, 2025

This “Ankylosing Spondylitis - Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Ankylosing Spondylitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Ankylosing Spondylitis: Understanding

Ankylosing Spondylitis: Overview

Ankylosing Spondylitis (Bekhterev's Disease) is a type of arthritis that causes inflammation in the joints and ligaments of the spine. It may also affect peripheral joints like the knees, ankles, and hips. Normally, the joints and ligaments in the spine help us move and bend. If you have ankylosing spondylitis, the inflammation in the joints and tissues of the spine can cause stiffness. In severe cases, this may cause the vertebrae (bones in the spine) to fuse (grow together). When the vertebrae fuse, it can lead to a rigid and inflexible spine. Many people with ankylosing spondylitis have mild episodes of back pain and stiffness that come and go. However, others have severe, ongoing pain with loss of flexibility in the spine. In addition, other symptoms may develop depending on which other areas of the body are affected by the disease. Some people with ankylosing spondylitis develop eye disease (uveitis), skin disease (psoriasis), or gut disease (inflammatory bowel disease). There is no cure for ankylosing spondylitis but there are many treatment options to help control symptoms. Recommended therapies may include exercise, physical and/or occupational therapy to improve mobility and posture, and medications to help manage pain, control inflammation, improve posture and body position, and slow the progression of the disease. The most common symptom is lower back and/or hip pain and stiffness, which may worsen during periods of rest or inactivity, and improve with movement and exercise. Symptoms may vary from person to person, with some experiencing mild episodes of pain that come and go, while others have chronic, severe pain. The disease can affect other areas of the body, leading to symptoms such as pain, stiffness, and inflammation in other joints, difficulty taking deep breaths, vision changes and eye pain, fatigue, loss of appetite and weight loss, skin rashes, and abdominal pain and loose bowel movements.

Imaging tests, such as X-rays and MRI scans, can reveal changes in joints and bones, but visible signs of ankylosing spondylitis may not be evident early in the disease. While blood tests can check for markers of inflammation and the HLA-B27 gene, there are no specific lab tests to identify ankylosing spondylitis, and many people who have the gene do not have the disease, while others may have the disease without the gene.

The treatment for ankylosing spondylitis typically involves a combination of approaches to alleviate symptoms, maintain flexibility, posture, and strength, and slow disease progression. This often includes the use of medications such as NSAIDs and biologics to manage pain and inflammation. Physiotherapy and regular exercise play a crucial role in reducing stiffness, preserving spinal mobility, and enhancing posture. In severe cases, surgery may be necessary for joint replacement or corrective procedures to address significant spinal deformities. Lifestyle modifications like maintaining a healthy weight, practicing good posture, using assistive devices when needed, staying active, and monitoring symptoms are also important aspects of managing the condition effectively. Collaborating closely with healthcare providers to create a personalized treatment plan is key to effectively managing ankylosing spondylitis.

'Ankylosing Spondylitis- Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Ankylosing Spondylitis pipeline landscape is provided which includes the disease overview and Ankylosing Spondylitis treatment guidelines. The assessment part of the report embraces, in depth Ankylosing Spondylitis commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Ankylosing Spondylitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Ankylosing Spondylitis R&D. The therapies under development are focused on novel approaches to treat/improve Ankylosing Spondylitis.

Ankylosing Spondylitis Emerging Drugs Chapters

This segment of the Ankylosing Spondylitis report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Ankylosing Spondylitis Emerging Drugs

AK111: Akeso

AK111 is a novel drug targeting IL-17A of autoimmune treatment diseases independently developed by the Company. AK111 is intended to be used for the treatment of psoriasis, ankylosing spondylitis and axial spondylitis. Through a combination of competitive blockers, namely IL-17A and IL-17RA, and blocking the biological activities of IL-17, AK111 has reached the efficacy in immune-related diseases in clinical therapies. Currently, the drug is in Phase III stage of its clinical trial for the treatment of ankylosing spondylitis.

Jaktinib: Suzhou Zelgen Biopharmaceuticals

Jaktinib hydrochloride, developed by Suzhou Zelgen Biopharmaceuticals, is a novel Janus kinase (JAK) inhibitor. It acts by targeting tyrosine protein kinases JAK1, JAK2, and JAK3, thereby inhibiting the JAK signaling pathway. This mechanism of action (moA) is crucial in treating various diseases, including myelofibrosis, graft versus host disease, rheumatoid arthritis, plaque psoriasis, idiopathic pulmonary fibrosis, autoimmune disorders, novel coronavirus pneumonia (COVID-19), and Ankylosing Spondylitis (Bekhterev's Disease). Currently, the drug is in Phase III stage of its clinical trial for the treatment of ankylosing spondylitis.

VC005: Jiangsu Vcare Pharmatech

VC005 is a novel, highly efficient, and selective JAK1 inhibitor, as well as a second-generation inhibitor, independently developed by Jiangsu Vcare. By selectively inhibiting JAK1 kinase, decreasing the inflammatory response, and reducing the activation of immune cells, VC005 displays high potential for the treatment of inflammatory and autoimmune diseases. The in vitro kinase test results indicated that VC005 exhibited a lower inhibitory activity against JAK2 kinase compared to an approved dominant JAK inhibitor, Upadacitinib, thus it is expected to alleviate many safety concerns associated with excessive JAK2 kinase inhibition. Currently, the drug is in Phase II stage of its clinical trial for the treatment of ankylosing spondylitis.

Ankylosing Spondylitis: Therapeutic Assessment

This segment of the report provides insights about the different Ankylosing Spondylitis drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Ankylosing Spondylitis

• There are approx. 20+ key companies which are developing the therapies for Ankylosing Spondylitis. The companies which have their Ankylosing Spondylitis drug candidates in the most advanced stage, i.e. Phase III include, Akeso.

Phases

The report covers around 20+ products under different Phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Ankylosing Spondylitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Ankylosing Spondylitis: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Ankylosing Spondylitis therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Ankylosing Spondylitis drugs.

Ankylosing Spondylitis Report Insights

• Ankylosing Spondylitis Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Ankylosing Spondylitis Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Ankylosing Spondylitis drugs?
• How many Ankylosing Spondylitis drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Ankylosing Spondylitis?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Ankylosing Spondylitis therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Ankylosing Spondylitis and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Jiangsu vcare pharmaceutical technology
• Lynk Pharmaceuticals
• Suzhou Zelgen Biopharmaceuticals
• Ucb biosciences
• Akeso
• NB Health Laboratory
• Funpep
• Shilpa Biologicals

Key Products

• VC005
• LNK01001
• Jaktinib
• Certolizumab Pegol
• AK111
• NBA-1603
• FPP-003
• Etanercept Biosimilar

This product will be delivered within 1-3 business days.